Who are the top shareholders of the Kilitch Drugs?

The top shareholder of Kilitch Drugs is Kilitch Company (Pharma) Limited, holding 41.22%. Other notable shareholders include Dipak Kanayalal Shah with 3.11% and individual investors collectively owning 25.57%.

The top shareholders of Kilitch Drugs are primarily the promoters, with Kilitch Company (Pharma) Limited holding the largest stake at 41.22%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not currently hold any shares in the company. Among public shareholders, Dipak Kanayalal Shah is the most significant, holding 3.11%. Additionally, individual investors collectively hold 25.57% of the shares.

Who are in the management team of Kilitch Drugs?

As of March 2023, the management team of Kilitch Drugs includes Mukund P Mehta (Managing Director), Bhavin M Mehta and Mira Bhavin Mehta (Whole-time Directors), and several Independent Directors: Hemang Engineer, Murti Vasudev Krishna, and Venkita Subramanian Rajan, along with Pushpa Nyoupane as Company Secretary & Compliance Officer.

As of March 2023, the management team of Kilitch Drugs includes the following individuals:<BR><BR>1. Mukund P Mehta - Managing Director<BR>2. Bhavin M Mehta - Whole-time Director<BR>3. Mira Bhavin Mehta - Whole-time Director<BR>4. Hemang Engineer - Independent Director<BR>5. Murti Vasudev Krishna - Independent Director<BR>6. Venkita Subramanian Rajan - Independent Director<BR>7. Pushpa Nyoupane - Company Secretary & Compliance Officer<BR><BR>These members play various roles in the company's governance and operations.

What does Kilitch Drugs do?

Kilitch Drugs (India) Ltd is a micro-cap pharmaceutical company founded in 1992, specializing in manufacturing and marketing a wide range of pharmaceutical formulations. As of March 2025, it reported net sales of 61 Cr and a net profit of 10 Cr, with a market cap of Rs 703 Cr.

Overview: <BR>Kilitch Drugs (India) Ltd is a leading and rapidly growing pharmaceutical company in the micro-cap category, specializing in the manufacturing, supplying, and marketing of a broad range of pharmaceutical formulations in various dosage forms.<BR><BR>History: <BR>Kilitch Drugs (India) Ltd was incorporated in May 1992. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 61 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 10 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 703 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 13.01% <BR>Price to Book: 3.48 <BR><BR>Contact Details: <BR>Address: C-301/2 MIDC TTC Indl Area, Pawane Village Thane Maharashtra : 400705 <BR>Tel: 91-022-27670322/27680913/65144185 <BR>Email: info@kilitch.com <BR>Website: http://www.kilitch.in

Has Kilitch Drugs declared dividend?

Kilitch Drugs has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 20, 2019. Despite this, the dividend yield is 0%, as the company has not provided ongoing dividends, though it has shown strong price returns over the years.

Kilitch Drugs has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 20 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 31.1%, with a dividend return of 0%, resulting in a total return of 31.1%.<BR><BR>For the 1-year period, the price return was 36.77%, with a dividend return of 0%, leading to a total return of 36.77%.<BR><BR>Over the 2-year period, the price return was 110.95%, with a dividend return of 0%, resulting in a total return of 110.95%.<BR><BR>In the 3-year period, the price return was 160.59%, with a dividend return of 0%, leading to a total return of 160.59%.<BR><BR>For the 4-year period, the price return was 171.11%, with a dividend return of 0%, resulting in a total return of 171.11%.<BR><BR>In the last 5 years, the price return was 342.78%, with a dividend return of 0%, leading to a total return of 342.78%.<BR><BR>Overall, Kilitch Drugs has declared a dividend, but the dividend yield remains at 0%. The company has shown substantial price returns over the years, indicating strong performance despite the lack of ongoing dividends.

Who are the peers of the Kilitch Drugs?

Kilitch Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, NGL Fine Chem, Venus Remedies, Shukra Pharma, and Nectar Lifesci. Kilitch Drugs has below-average management risk and good growth, with a 1-year return of 26.55%, compared to Divi's Lab's highest return of 51.69% and NGL Fine Chem's lowest at -52.32%.

Peers: The peers of Kilitch Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, NGL Fine Chem, Venus Remedies, Shukra Pharma., and Nectar Lifesci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at NGL Fine Chem, Venus Remedies, Shukra Pharma., and Sakar Healthcare, and the rest. Below Average management risk is attributed to Kilitch Drugs and Nectar Lifesci. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Kilitch Drugs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, NGL Fine Chem, and Nectar Lifesci. Average growth is seen at Venus Remedies and the rest, while Good growth is reported for Shukra Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and NGL Fine Chem, while Good capital structure is attributed to Kilitch Drugs and Shukra Pharma., and Average capital structure is observed at Venus Remedies and Sakar Healthcare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is NGL Fine Chem at -52.32%. Kilitch Drugs has a 1-year return of 26.55%, which is significantly higher than NGL Fine Chem but lower than Divi's Lab. Additionally, NGL Fine Chem and Nectar Lifesci. have negative six-month returns.

How big is Kilitch Drugs?

As of 24th July, Kilitch Drugs (India) Ltd has a market capitalization of 757.00 Cr, classifying it as a Micro Cap company, with recent net sales of 198.32 Cr and a net profit of 26.32 Cr. The balance sheet for March 2024 shows shareholder's funds of 176.29 Cr and total assets of 237.50 Cr.

As of 24th July, Kilitch Drugs (India) Ltd has a market capitalization of 757.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Kilitch Drugs reported Net Sales of 198.32 Cr and a Net Profit of 26.32 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 176.29 Cr and Total Assets of 237.50 Cr.

Are Kilitch Drugs latest results good or bad?

Kilitch Drugs' latest results are poor, with net sales down 29.54% and profit before tax plummeting by 84.5%. Increased interest expenses and a high debt-equity ratio further indicate financial challenges for the company.

Kilitch Drugs' latest financial results indicate a challenging period for the company. The performance has shown significant declines across several key metrics. <BR><BR>Net sales for the quarter ending June 2025 fell by 29.54%, dropping to Rs 43.14 crore, compared to the previous quarter. This decline is part of a broader trend, as net sales have decreased by 13% from the average of the last four quarters. <BR><BR>Profit Before Tax (PBT) has also taken a substantial hit, decreasing by 84.5% to Rs 0.89 crore, while Profit After Tax (PAT) fell by 54% to Rs 3.03 crore. This decline in profitability is concerning, especially given that the company had previously reported stronger figures.<BR><BR>Additionally, the company's interest expenses have surged by 83.04%, reflecting increased borrowing costs, which could further strain its financial health. The inventory turnover ratio has reached its lowest point, suggesting difficulties in selling inventory, and the debt-equity ratio is at its highest in five half-year periods, indicating a reliance on debt to support operations.<BR><BR>Overall, these results suggest that Kilitch Drugs is facing significant challenges, and the financial performance can be characterized as poor in the latest quarter.

Should I buy, sell or hold Kilitch Drugs?

When is the next results date for Kilitch Drugs?

The next results date for Kilitch Drugs is 13 November 2025.

The next results date for Kilitch Drugs is scheduled for 13 November 2025.

How has been the historical performance of Kilitch Drugs?

Kilitch Drugs has experienced significant growth in net sales and profitability, with net sales increasing from INR 53.32 crore in March 2020 to INR 198.32 crore in March 2025, and profit after tax rising from INR 0.84 crore to INR 24.94 crore during the same period. The company's earnings per share also surged from INR 0.54 to INR 16.25, reflecting enhanced shareholder value.

Answer:<BR>Kilitch Drugs has shown significant growth in its historical performance, particularly in net sales and profitability over the past several years.<BR><BR>Breakdown:<BR>Kilitch Drugs' net sales have consistently increased from INR 53.32 crore in March 2020 to INR 198.32 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, reaching INR 198.32 crore in March 2025, up from INR 82.49 crore in March 2019. The company's operating profit (PBDIT) also saw substantial growth, rising from INR 4.33 crore in March 2020 to INR 42.63 crore in March 2025, indicating improved operational efficiency. Profit before tax increased from INR 1.61 crore in March 2020 to INR 34.47 crore in March 2025, while profit after tax surged from INR 0.84 crore to INR 24.94 crore in the same period. The earnings per share (EPS) rose significantly from INR 0.54 in March 2020 to INR 16.25 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 141.86 crore in March 2020 to INR 309.90 crore in March 2025, with total liabilities also increasing, primarily due to long-term borrowings that began in March 2024. The cash flow from operating activities improved to INR 17 crore in March 2025, compared to a negative cash flow in March 2024, indicating a recovery in operational cash generation. Overall, Kilitch Drugs has demonstrated robust growth in sales, profits, and asset base over the years.

Is Kilitch Drugs overvalued or undervalued?

As of November 25, 2025, Kilitch Drugs is fairly valued with a PE Ratio of 22.32 and strong growth potential, outperforming peers like Sun Pharma and Divi's Lab, while also delivering a 14.87% return compared to the Sensex's 5.59%.

As of 25 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 22.32, an EV to EBITDA of 19.36, and a PEG Ratio of 0.41, indicating potential for growth relative to its price. <BR><BR>In comparison to its peers, Kilitch Drugs stands out with its fair valuation against Sun Pharma, which is considered expensive with a PE Ratio of 36.81, and Divi's Lab, which is very expensive at a PE Ratio of 68.57. Additionally, while Kilitch has a ROCE of 10.78% and ROE of 10.38%, it has performed well against the Sensex over the past year, returning 14.87% compared to the Sensex's 5.59%.

Which are the latest news on Kilitch Drugs?

Why is Kilitch Drugs falling/rising?

As of 04-Dec, Kilitch Drugs (India) Ltd's stock price is rising slightly at 343.25, but it has declined over the past week and month. Despite today's gains, the overall sentiment is cautious due to decreased investor participation and a bearish trend.

As of 04-Dec, Kilitch Drugs (India) Ltd is experiencing a slight rise in its stock price, currently at 343.25, with a change of 1.45 (0.42%) upwards. The stock opened the day with a significant gain of 4.77%, reaching an intraday high of Rs 360, which reflects a 5.32% increase at its peak. However, despite this rise, the stock has shown a negative performance over the past week and month, with declines of 4.13% and 12.23%, respectively. <BR><BR>The stock's performance today has been described as inline with the sector, but it is trading lower than its moving averages across various time frames, indicating a potential bearish trend. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 75.79% compared to the 5-day average. This decline in participation, coupled with high volatility of 5.51% intraday, suggests that while there may be short-term gains, the overall sentiment towards the stock remains cautious. <BR><BR>In summary, while Kilitch Drugs is currently rising in price today, the broader context of its recent performance and declining investor interest indicates a complex situation that may not sustain this upward movement in the longer term.

Is Kilitch Drugs technically bullish or bearish?

As of December 4, 2025, the technical trend is mildly bearish, indicated by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and Dow Theory, suggesting weak bearish sentiment in the short to medium term.

As of 4 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart. Bollinger Bands also indicate a mildly bearish trend on both the weekly and monthly time frames. Moving averages are bearish on the daily chart, while the KST shows a mildly bullish stance weekly but is mildly bearish monthly. Dow Theory presents a mixed view with a mildly bearish signal weekly and a mildly bullish signal monthly. Overall, the combination of these indicators suggests a weak bearish sentiment in the short to medium term.